Bone Marrow-Derived CD44+Cells Migrate to Tissue-Engineered Constructs via SDF-1/CXCR4-JNK Pathway and Aid Bone Repair

Yanzhu Lu, Junchao Xing, Xiaolong Yin, Xiaobo Zhu, Aijun Yang, Jiyue Luo, Jing Gou, Shiwu Dong, Jianzhong Xu, Tianyong HouStem 2019 · DOI

TL;DR

This study reveals that bone marrow-derived CD44+ cells are crucial for bone repair when using tissue-engineered constructs (TECs). Their migration to the injury site is orchestrated by the SDF-1/CXCR4-JNK signaling pathway, offering a new target for enhancing bone regeneration therapies.

What Problem Does This Paper Address?

Large segmental bone defects (LSBDs) are a significant clinical challenge, and tissue-engineered constructs (TECs) show promise for repair. While it's understood that host cells play a role in TEC-mediated bone repair, their specific identity, origin, and the mechanisms that recruit them to the defect site have remained largely unknown. This lack of understanding hinders the optimization of TEC-based therapies. The paper aims to elucidate the source and migratory pathways of these crucial host cells.

Methods

The researchers developed a sophisticated multi-model approach to track host cells:

  • GFP+ Bone Marrow Transplantation (GFP-BMT): This allowed them to distinguish cells originating from the bone marrow (BM) of a donor mouse.
  • Parabiosis: Two mice (one GFP-BMT and one wild-type) were surgically joined, creating a shared circulatory system. This enabled the observation of cell migration between the two animals, particularly from the wild-type mouse into the defect site of the GFP-BMT mouse.
  • Femoral Large Segmental Bone Defect (LSBD) Model: A standardized critical-sized defect was created in the femur of the mice to mimic human bone injuries.
  • Tissue-Engineered Constructs (TECs): These were created by seeding mesenchymal stem cells (MSCs) onto decalcified bone matrix (DBM) scaffolds.
  • In Vivo and In Vitro Assays:
    • Imaging (IVIS): Used to track GFP+ cells in real-time.
  • Immunofluorescence Staining: Confirmed the presence and co-localization of GFP+ and CD44+ cells at the defect site.
  • Flow Cytometry (FACS): Used for cell sorting and quantifying specific cell populations (e.g., CD44+ cells).
  • ELISA: Measured the concentration of SDF-1 in different tissues.
  • Western Blotting: Analyzed the expression of key signaling proteins (e.g., CXCR4, p-JNK).
  • Transwell Migration Assays: Investigated the chemotactic response of CD44+ BM cells to various stimuli and inhibitors in vitro.
  • RT-PCR: Assessed gene expression levels of key migratory factors.
  • Pharmacological Inhibition: The study utilized specific inhibitors (AMD3100 for CXCR4 and SP600125 for JNK) to probe the roles of these signaling pathways in cell migration.

Datasets

Not discussed in the paper. The study relies on experimental data generated from animal models and in vitro assays.

Key Insights and Ideas

  • Bone Marrow is the Primary Source: The study definitively shows that the majority of host cells recruited to aid bone repair within TECs originate from the bone marrow. This is a critical piece of information for understanding the host response.
  • CD44 is a Key Marker for Migratory Cells: The research highlights that these bone marrow-derived cells predominantly express CD44. This suggests CD44 plays a significant role in their ability to migrate to the injury site.
  • SDF-1/CXCR4 Axis is Essential: The study demonstrates that the chemokine SDF-1 and its receptor CXCR4 are central to the migration of CD44+ BM cells. Blocking CXCR4 significantly impacts this migration.
  • JNK Pathway is the Downstream Effector: The research pinpoints the JNK signaling pathway as a crucial downstream mediator of SDF-1/CXCR4 signaling in controlling CD44+ cell migration. Inhibiting JNK severely impairs their movement.
  • TEC Superiority Explained: The findings provide a mechanistic explanation for why TECs (with MSCs) are more effective than DBM scaffolds alone – they actively recruit and leverage these CD44+ BM cells via the identified signaling pathway.

Key Results

  • Increased Recruitment to TECs: Significantly more GFP+ cells were recruited to TECs compared to DBM scaffolds.
  • CD44+ Dominance: The majority of recruited GFP+ cells in TECs were CD44 positive.
  • SDF-1/CXCR4 Dependence: AMD3100 (CXCR4 antagonist) treatment led to increased CD44+ cells in peripheral blood but decreased recruitment to TECs, indicating its role in homing.
  • JNK Inhibition Impairs Migration: SP600125 (JNK inhibitor) significantly reduced both circulating CD44+ BM cells and their recruitment to TECs.
  • Protein and Gene Expression Changes: Inhibition of JNK affected the expression of downstream molecules like Arpin and Arp2/3, which are involved in cell migration machinery.

Limitations and Future Work

  • Relationship between SDF-1/CXCR4-JNK and CD44: While the study demonstrates the involvement of these components, further research is needed to fully elucidate the intricate relationship between the SDF-1/CXCR4-JNK pathway and CD44 in the context of cell migration.
  • Donor-Host Cell Interactions: The paper suggests that understanding donor-host cell interactions is crucial. Future studies could expand on this to refine therapeutic strategies.
  • Therapeutic Strategy Development: The authors propose that these findings could pave the way for developing novel strategies to enhance the reparative capacity of TECs and potentially reduce costs and adverse effects. This implies future work could focus on manipulating this pathway for therapeutic benefit.

Summary updated

Abstract

Together, we demonstrated that during bone repair promoted by TECs, BM-derived CD44<sup>+</sup> cells were essential and their migration towards TECs could be regulated by the SDF-1/CXCR4-JNK signaling pathway.
BibTeX
@inproceedings{lu2019bone,
  author = {Yanzhu Lu and Junchao Xing and Xiaolong Yin and Xiaobo Zhu and Aijun Yang and Jiyue Luo and Jing Gou and Shiwu Dong and Jianzhong Xu and Tianyong Hou},
  title = {{Bone Marrow-Derived CD44<sup>+</sup>Cells Migrate to Tissue-Engineered Constructs via SDF-1/CXCR4-JNK Pathway and Aid Bone Repair}},
  booktitle = {Stem},
  year = {2019},
  doi = {10.1155/2019/1513526},
}
Figure